Footnotes
This manuscript has recently been accepted for publication in the ERJ Open Research. It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJOR online. Please open or download the PDF to view this article.
Conflict of interest: NW: has no conflicts of interest to disclose.
Conflict of interest: RH: has no conflicts of interest to disclose.
Conflict of interest: BM: has no conflicts of interest to disclose.
Conflict of interest: LS: has no conflicts of interest to disclose.
Conflict of interest: JA: reports personal fees and non-financial support from MSD; personal fees from BMS, Boehringer Ingelheim, Amphera, Eli Lilly, Takeda, Bayer, Roche, Astra Zeneca outside the submitted work. In addition, JA has a patent on allogenic tumor cell lysate licensed to Amphera, a patent combination immunotherapy in cancer pending, and a patent biomarker for immunotherapy pending.
Conflict of interest: OM: has no conflicts of interest to disclose.
Conflict of interest: MH: has no conflicts of interest to disclose.
This is a PDF-only article. Please click on the PDF link above to read it.
- Received January 26, 2022.
- Accepted May 3, 2022.
- Copyright ©The authors 2022
This version is distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 4.0. For commercial reproduction rights and permissions contact permissions{at}ersnet.org
